ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Acute Migraine Medications Market Research Report 2025
Published Date: July 2025
|
Report Code: QYRE-Auto-15U8088
Home | Market Reports | Health| Health Conditions| Pain Management
Global and China Acute Migraine Medications Market Insights Forecast to 2027
BUY CHAPTERS

Global Acute Migraine Medications Market Research Report 2025

Code: QYRE-Auto-15U8088
Report
July 2025
Pages:81
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
GSK
TEVA
Pfizer Inc
Novartis
Merck
Sun Pharma
Grunenthal
Endo Pharmaceuticals

Acute Migraine Medications Market Size

The global market for Acute Migraine Medications was valued at US$ 2254 million in the year 2024 and is projected to reach a revised size of US$ 2839 million by 2031, growing at a CAGR of 3.4% during the forecast period.

Acute Migraine Medications Market

Acute Migraine Medications Market

A migraine is an episodic and unpredictable headache disorder that presents with disabling attack. Migraine is one of the most frequent disabling neurological conditions with a major impact on the patient’s quality of life. Migraine has been described as a chronic disorder that characterized with attacks. Attacks are characterized by moderate–severe, often unilateral, pulsating headache attacks, typically lasting 4 to 72 hours.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Acute Migraine Medications, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Acute Migraine Medications.
The Acute Migraine Medications market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Acute Migraine Medications market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Acute Migraine Medications manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Acute Migraine Medications Market Report

Report Metric Details
Report Name Acute Migraine Medications Market
Accounted market size in year US$ 2254 million
Forecasted market size in 2031 US$ 2839 million
CAGR 3.4%
Base Year year
Forecasted years 2025 - 2031
Segment by Type
Segment by Application
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company GSK, Teva, Pfizer, Novartis, Merck, Sun Pharma, Grunenthal, Endo Pharmaceuticals
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Acute Migraine Medications manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Acute Migraine Medications in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report. 

FAQ for this report

How fast is Acute Migraine Medications Market growing?

Ans: The Acute Migraine Medications Market witnessing a CAGR of 3.4% during the forecast period 2025-2031.

What is the Acute Migraine Medications Market size in 2031?

Ans: The Acute Migraine Medications Market size in 2031 will be US$ 2839 million.

Who are the main players in the Acute Migraine Medications Market report?

Ans: The main players in the Acute Migraine Medications Market are GSK, Teva, Pfizer, Novartis, Merck, Sun Pharma, Grunenthal, Endo Pharmaceuticals

What are the Application segmentation covered in the Acute Migraine Medications Market report?

Ans: The Applications covered in the Acute Migraine Medications Market report are Drug Stores, Hospital Pharmacies

What are the Type segmentation covered in the Acute Migraine Medications Market report?

Ans: The Types covered in the Acute Migraine Medications Market report are Triptans, NSAIDs, Others

Recommended Reports

Migraine and Neurology

Pain and Analgesics

Alzheimer's and CNS

1 Acute Migraine Medications Market Overview
1.1 Product Definition
1.2 Acute Migraine Medications by Type
1.2.1 Global Acute Migraine Medications Market Value Comparison by Type (2024 VS 2031)
1.2.2 Triptans
1.2.3 NSAIDs
1.2.4 Others
1.3 Acute Migraine Medications by Application
1.3.1 Global Acute Migraine Medications Market Value by Application (2024 VS 2031)
1.3.2 Drug Stores
1.3.3 Hospital Pharmacies
1.4 Global Acute Migraine Medications Market Size Estimates and Forecasts
1.4.1 Global Acute Migraine Medications Revenue 2020-2031
1.4.2 Global Acute Migraine Medications Sales 2020-2031
1.4.3 Global Acute Migraine Medications Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Acute Migraine Medications Market Competition by Manufacturers
2.1 Global Acute Migraine Medications Sales Market Share by Manufacturers (2020-2025)
2.2 Global Acute Migraine Medications Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Acute Migraine Medications Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Acute Migraine Medications, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Acute Migraine Medications, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Acute Migraine Medications, Product Type & Application
2.7 Global Key Manufacturers of Acute Migraine Medications, Date of Enter into This Industry
2.8 Global Acute Migraine Medications Market Competitive Situation and Trends
2.8.1 Global Acute Migraine Medications Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Acute Migraine Medications Players Market Share by Revenue
2.8.3 Global Acute Migraine Medications Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Acute Migraine Medications Market Scenario by Region
3.1 Global Acute Migraine Medications Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Acute Migraine Medications Sales by Region: 2020-2031
3.2.1 Global Acute Migraine Medications Sales by Region: 2020-2025
3.2.2 Global Acute Migraine Medications Sales by Region: 2026-2031
3.3 Global Acute Migraine Medications Revenue by Region: 2020-2031
3.3.1 Global Acute Migraine Medications Revenue by Region: 2020-2025
3.3.2 Global Acute Migraine Medications Revenue by Region: 2026-2031
3.4 North America Acute Migraine Medications Market Facts & Figures by Country
3.4.1 North America Acute Migraine Medications Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Acute Migraine Medications Sales by Country (2020-2031)
3.4.3 North America Acute Migraine Medications Revenue by Country (2020-2031)
3.4.4 United States
3.4.5 Canada
3.5 Europe Acute Migraine Medications Market Facts & Figures by Country
3.5.1 Europe Acute Migraine Medications Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Acute Migraine Medications Sales by Country (2020-2031)
3.5.3 Europe Acute Migraine Medications Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Acute Migraine Medications Market Facts & Figures by Region
3.6.1 Asia Pacific Acute Migraine Medications Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Acute Migraine Medications Sales by Region (2020-2031)
3.6.3 Asia Pacific Acute Migraine Medications Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Acute Migraine Medications Market Facts & Figures by Country
3.7.1 Latin America Acute Migraine Medications Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Acute Migraine Medications Sales by Country (2020-2031)
3.7.3 Latin America Acute Migraine Medications Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Acute Migraine Medications Market Facts & Figures by Country
3.8.1 Middle East and Africa Acute Migraine Medications Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Acute Migraine Medications Sales by Country (2020-2031)
3.8.3 Middle East and Africa Acute Migraine Medications Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Acute Migraine Medications Sales by Type (2020-2031)
4.1.1 Global Acute Migraine Medications Sales by Type (2020-2025)
4.1.2 Global Acute Migraine Medications Sales by Type (2026-2031)
4.1.3 Global Acute Migraine Medications Sales Market Share by Type (2020-2031)
4.2 Global Acute Migraine Medications Revenue by Type (2020-2031)
4.2.1 Global Acute Migraine Medications Revenue by Type (2020-2025)
4.2.2 Global Acute Migraine Medications Revenue by Type (2026-2031)
4.2.3 Global Acute Migraine Medications Revenue Market Share by Type (2020-2031)
4.3 Global Acute Migraine Medications Price by Type (2020-2031)
5 Segment by Application
5.1 Global Acute Migraine Medications Sales by Application (2020-2031)
5.1.1 Global Acute Migraine Medications Sales by Application (2020-2025)
5.1.2 Global Acute Migraine Medications Sales by Application (2026-2031)
5.1.3 Global Acute Migraine Medications Sales Market Share by Application (2020-2031)
5.2 Global Acute Migraine Medications Revenue by Application (2020-2031)
5.2.1 Global Acute Migraine Medications Revenue by Application (2020-2025)
5.2.2 Global Acute Migraine Medications Revenue by Application (2026-2031)
5.2.3 Global Acute Migraine Medications Revenue Market Share by Application (2020-2031)
5.3 Global Acute Migraine Medications Price by Application (2020-2031)
6 Key Companies Profiled
6.1 GSK
6.1.1 GSK Company Information
6.1.2 GSK Description and Business Overview
6.1.3 GSK Acute Migraine Medications Sales, Revenue and Gross Margin (2020-2025)
6.1.4 GSK Acute Migraine Medications Product Portfolio
6.1.5 GSK Recent Developments/Updates
6.2 Teva
6.2.1 Teva Company Information
6.2.2 Teva Description and Business Overview
6.2.3 Teva Acute Migraine Medications Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Teva Acute Migraine Medications Product Portfolio
6.2.5 Teva Recent Developments/Updates
6.3 Pfizer
6.3.1 Pfizer Company Information
6.3.2 Pfizer Description and Business Overview
6.3.3 Pfizer Acute Migraine Medications Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Pfizer Acute Migraine Medications Product Portfolio
6.3.5 Pfizer Recent Developments/Updates
6.4 Novartis
6.4.1 Novartis Company Information
6.4.2 Novartis Description and Business Overview
6.4.3 Novartis Acute Migraine Medications Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Novartis Acute Migraine Medications Product Portfolio
6.4.5 Novartis Recent Developments/Updates
6.5 Merck
6.5.1 Merck Company Information
6.5.2 Merck Description and Business Overview
6.5.3 Merck Acute Migraine Medications Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Merck Acute Migraine Medications Product Portfolio
6.5.5 Merck Recent Developments/Updates
6.6 Sun Pharma
6.6.1 Sun Pharma Company Information
6.6.2 Sun Pharma Description and Business Overview
6.6.3 Sun Pharma Acute Migraine Medications Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Sun Pharma Acute Migraine Medications Product Portfolio
6.6.5 Sun Pharma Recent Developments/Updates
6.7 Grunenthal
6.7.1 Grunenthal Company Information
6.7.2 Grunenthal Description and Business Overview
6.7.3 Grunenthal Acute Migraine Medications Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Grunenthal Acute Migraine Medications Product Portfolio
6.7.5 Grunenthal Recent Developments/Updates
6.8 Endo Pharmaceuticals
6.8.1 Endo Pharmaceuticals Company Information
6.8.2 Endo Pharmaceuticals Description and Business Overview
6.8.3 Endo Pharmaceuticals Acute Migraine Medications Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Endo Pharmaceuticals Acute Migraine Medications Product Portfolio
6.8.5 Endo Pharmaceuticals Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Acute Migraine Medications Industry Chain Analysis
7.2 Acute Migraine Medications Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Acute Migraine Medications Production Mode & Process Analysis
7.4 Acute Migraine Medications Sales and Marketing
7.4.1 Acute Migraine Medications Sales Channels
7.4.2 Acute Migraine Medications Distributors
7.5 Acute Migraine Medications Customer Analysis
8 Acute Migraine Medications Market Dynamics
8.1 Acute Migraine Medications Industry Trends
8.2 Acute Migraine Medications Market Drivers
8.3 Acute Migraine Medications Market Challenges
8.4 Acute Migraine Medications Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
FEATURED COMPANIES
GSK
TEVA
Pfizer Inc
Novartis
Merck
Sun Pharma
Grunenthal
Endo Pharmaceuticals
List of Tables
 Table 1. Global Acute Migraine Medications Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
 Table 2. Global Acute Migraine Medications Market Value by Application (2024 VS 2031) & (US$ Million)
 Table 3. Global Acute Migraine Medications Market Competitive Situation by Manufacturers in 2024
 Table 4. Global Acute Migraine Medications Sales (K Units) of Key Manufacturers (2020-2025)
 Table 5. Global Acute Migraine Medications Sales Market Share by Manufacturers (2020-2025)
 Table 6. Global Acute Migraine Medications Revenue (US$ Million) by Manufacturers (2020-2025)
 Table 7. Global Acute Migraine Medications Revenue Share by Manufacturers (2020-2025)
 Table 8. Global Market Acute Migraine Medications Average Price (US$/Unit) of Key Manufacturers (2020-2025)
 Table 9. Global Key Players of Acute Migraine Medications, Industry Ranking, 2022 VS 2023 VS 2024
 Table 10. Global Key Manufacturers of Acute Migraine Medications, Manufacturing Sites & Headquarters
 Table 11. Global Key Manufacturers of Acute Migraine Medications, Product Type & Application
 Table 12. Global Key Manufacturers of Acute Migraine Medications, Date of Enter into This Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Acute Migraine Medications by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Acute Migraine Medications as of 2024)
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Acute Migraine Medications Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 17. Global Acute Migraine Medications Sales by Region (2020-2025) & (K Units)
 Table 18. Global Acute Migraine Medications Sales Market Share by Region (2020-2025)
 Table 19. Global Acute Migraine Medications Sales by Region (2026-2031) & (K Units)
 Table 20. Global Acute Migraine Medications Sales Market Share by Region (2026-2031)
 Table 21. Global Acute Migraine Medications Revenue by Region (2020-2025) & (US$ Million)
 Table 22. Global Acute Migraine Medications Revenue Market Share by Region (2020-2025)
 Table 23. Global Acute Migraine Medications Revenue by Region (2026-2031) & (US$ Million)
 Table 24. Global Acute Migraine Medications Revenue Market Share by Region (2026-2031)
 Table 25. North America Acute Migraine Medications Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 26. North America Acute Migraine Medications Sales by Country (2020-2025) & (K Units)
 Table 27. North America Acute Migraine Medications Sales by Country (2026-2031) & (K Units)
 Table 28. North America Acute Migraine Medications Revenue by Country (2020-2025) & (US$ Million)
 Table 29. North America Acute Migraine Medications Revenue by Country (2026-2031) & (US$ Million)
 Table 30. Europe Acute Migraine Medications Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 31. Europe Acute Migraine Medications Sales by Country (2020-2025) & (K Units)
 Table 32. Europe Acute Migraine Medications Sales by Country (2026-2031) & (K Units)
 Table 33. Europe Acute Migraine Medications Revenue by Country (2020-2025) & (US$ Million)
 Table 34. Europe Acute Migraine Medications Revenue by Country (2026-2031) & (US$ Million)
 Table 35. Asia Pacific Acute Migraine Medications Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 36. Asia Pacific Acute Migraine Medications Sales by Region (2020-2025) & (K Units)
 Table 37. Asia Pacific Acute Migraine Medications Sales by Region (2026-2031) & (K Units)
 Table 38. Asia Pacific Acute Migraine Medications Revenue by Region (2020-2025) & (US$ Million)
 Table 39. Asia Pacific Acute Migraine Medications Revenue by Region (2026-2031) & (US$ Million)
 Table 40. Latin America Acute Migraine Medications Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 41. Latin America Acute Migraine Medications Sales by Country (2020-2025) & (K Units)
 Table 42. Latin America Acute Migraine Medications Sales by Country (2026-2031) & (K Units)
 Table 43. Latin America Acute Migraine Medications Revenue by Country (2020-2025) & (US$ Million)
 Table 44. Latin America Acute Migraine Medications Revenue by Country (2026-2031) & (US$ Million)
 Table 45. Middle East and Africa Acute Migraine Medications Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 46. Middle East and Africa Acute Migraine Medications Sales by Country (2020-2025) & (K Units)
 Table 47. Middle East and Africa Acute Migraine Medications Sales by Country (2026-2031) & (K Units)
 Table 48. Middle East and Africa Acute Migraine Medications Revenue by Country (2020-2025) & (US$ Million)
 Table 49. Middle East and Africa Acute Migraine Medications Revenue by Country (2026-2031) & (US$ Million)
 Table 50. Global Acute Migraine Medications Sales (K Units) by Type (2020-2025)
 Table 51. Global Acute Migraine Medications Sales (K Units) by Type (2026-2031)
 Table 52. Global Acute Migraine Medications Sales Market Share by Type (2020-2025)
 Table 53. Global Acute Migraine Medications Sales Market Share by Type (2026-2031)
 Table 54. Global Acute Migraine Medications Revenue (US$ Million) by Type (2020-2025)
 Table 55. Global Acute Migraine Medications Revenue (US$ Million) by Type (2026-2031)
 Table 56. Global Acute Migraine Medications Revenue Market Share by Type (2020-2025)
 Table 57. Global Acute Migraine Medications Revenue Market Share by Type (2026-2031)
 Table 58. Global Acute Migraine Medications Price (US$/Unit) by Type (2020-2025)
 Table 59. Global Acute Migraine Medications Price (US$/Unit) by Type (2026-2031)
 Table 60. Global Acute Migraine Medications Sales (K Units) by Application (2020-2025)
 Table 61. Global Acute Migraine Medications Sales (K Units) by Application (2026-2031)
 Table 62. Global Acute Migraine Medications Sales Market Share by Application (2020-2025)
 Table 63. Global Acute Migraine Medications Sales Market Share by Application (2026-2031)
 Table 64. Global Acute Migraine Medications Revenue (US$ Million) by Application (2020-2025)
 Table 65. Global Acute Migraine Medications Revenue (US$ Million) by Application (2026-2031)
 Table 66. Global Acute Migraine Medications Revenue Market Share by Application (2020-2025)
 Table 67. Global Acute Migraine Medications Revenue Market Share by Application (2026-2031)
 Table 68. Global Acute Migraine Medications Price (US$/Unit) by Application (2020-2025)
 Table 69. Global Acute Migraine Medications Price (US$/Unit) by Application (2026-2031)
 Table 70. GSK Company Information
 Table 71. GSK Description and Business Overview
 Table 72. GSK Acute Migraine Medications Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 73. GSK Acute Migraine Medications Product
 Table 74. GSK Recent Developments/Updates
 Table 75. Teva Company Information
 Table 76. Teva Description and Business Overview
 Table 77. Teva Acute Migraine Medications Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 78. Teva Acute Migraine Medications Product
 Table 79. Teva Recent Developments/Updates
 Table 80. Pfizer Company Information
 Table 81. Pfizer Description and Business Overview
 Table 82. Pfizer Acute Migraine Medications Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 83. Pfizer Acute Migraine Medications Product
 Table 84. Pfizer Recent Developments/Updates
 Table 85. Novartis Company Information
 Table 86. Novartis Description and Business Overview
 Table 87. Novartis Acute Migraine Medications Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 88. Novartis Acute Migraine Medications Product
 Table 89. Novartis Recent Developments/Updates
 Table 90. Merck Company Information
 Table 91. Merck Description and Business Overview
 Table 92. Merck Acute Migraine Medications Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 93. Merck Acute Migraine Medications Product
 Table 94. Merck Recent Developments/Updates
 Table 95. Sun Pharma Company Information
 Table 96. Sun Pharma Description and Business Overview
 Table 97. Sun Pharma Acute Migraine Medications Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 98. Sun Pharma Acute Migraine Medications Product
 Table 99. Sun Pharma Recent Developments/Updates
 Table 100. Grunenthal Company Information
 Table 101. Grunenthal Description and Business Overview
 Table 102. Grunenthal Acute Migraine Medications Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 103. Grunenthal Acute Migraine Medications Product
 Table 104. Grunenthal Recent Developments/Updates
 Table 105. Endo Pharmaceuticals Company Information
 Table 106. Endo Pharmaceuticals Description and Business Overview
 Table 107. Endo Pharmaceuticals Acute Migraine Medications Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 108. Endo Pharmaceuticals Acute Migraine Medications Product
 Table 109. Endo Pharmaceuticals Recent Developments/Updates
 Table 110. Key Raw Materials Lists
 Table 111. Raw Materials Key Suppliers Lists
 Table 112. Acute Migraine Medications Distributors List
 Table 113. Acute Migraine Medications Customers List
 Table 114. Acute Migraine Medications Market Trends
 Table 115. Acute Migraine Medications Market Drivers
 Table 116. Acute Migraine Medications Market Challenges
 Table 117. Acute Migraine Medications Market Restraints
 Table 118. Research Programs/Design for This Report
 Table 119. Key Data Information from Secondary Sources
 Table 120. Key Data Information from Primary Sources
 Table 121. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Acute Migraine Medications
 Figure 2. Global Acute Migraine Medications Market Value Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Acute Migraine Medications Market Share by Type: 2024 & 2031
 Figure 4. Triptans Product Picture
 Figure 5. NSAIDs Product Picture
 Figure 6. Others Product Picture
 Figure 7. Global Acute Migraine Medications Market Value by Application (2020-2031) & (US$ Million)
 Figure 8. Global Acute Migraine Medications Market Share by Application: 2024 & 2031
 Figure 9. Drug Stores
 Figure 10. Hospital Pharmacies
 Figure 11. Global Acute Migraine Medications Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 12. Global Acute Migraine Medications Market Size (2020-2031) & (US$ Million)
 Figure 13. Global Acute Migraine Medications Sales (2020-2031) & (K Units)
 Figure 14. Global Acute Migraine Medications Average Price (US$/Unit) & (2020-2031)
 Figure 15. Acute Migraine Medications Report Years Considered
 Figure 16. Acute Migraine Medications Sales Share by Manufacturers in 2024
 Figure 17. Global Acute Migraine Medications Revenue Share by Manufacturers in 2024
 Figure 18. Global 5 and 10 Largest Acute Migraine Medications Players: Market Share by Revenue in Acute Migraine Medications in 2024
 Figure 19. Acute Migraine Medications Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
 Figure 20. Global Acute Migraine Medications Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Figure 21. North America Acute Migraine Medications Sales Market Share by Country (2020-2031)
 Figure 22. North America Acute Migraine Medications Revenue Market Share by Country (2020-2031)
 Figure 23. United States Acute Migraine Medications Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 24. Canada Acute Migraine Medications Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 25. Europe Acute Migraine Medications Sales Market Share by Country (2020-2031)
 Figure 26. Europe Acute Migraine Medications Revenue Market Share by Country (2020-2031)
 Figure 27. Germany Acute Migraine Medications Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 28. France Acute Migraine Medications Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 29. U.K. Acute Migraine Medications Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 30. Italy Acute Migraine Medications Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 31. Russia Acute Migraine Medications Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 32. Asia Pacific Acute Migraine Medications Sales Market Share by Region (2020-2031)
 Figure 33. Asia Pacific Acute Migraine Medications Revenue Market Share by Region (2020-2031)
 Figure 34. China Acute Migraine Medications Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 35. Japan Acute Migraine Medications Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 36. South Korea Acute Migraine Medications Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 37. India Acute Migraine Medications Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 38. Australia Acute Migraine Medications Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 39. China Taiwan Acute Migraine Medications Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 40. Indonesia Acute Migraine Medications Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 41. Thailand Acute Migraine Medications Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 42. Malaysia Acute Migraine Medications Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 43. Latin America Acute Migraine Medications Sales Market Share by Country (2020-2031)
 Figure 44. Latin America Acute Migraine Medications Revenue Market Share by Country (2020-2031)
 Figure 45. Mexico Acute Migraine Medications Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 46. Brazil Acute Migraine Medications Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 47. Argentina Acute Migraine Medications Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 48. Middle East and Africa Acute Migraine Medications Sales Market Share by Country (2020-2031)
 Figure 49. Middle East and Africa Acute Migraine Medications Revenue Market Share by Country (2020-2031)
 Figure 50. Turkey Acute Migraine Medications Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 51. Saudi Arabia Acute Migraine Medications Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 52. UAE Acute Migraine Medications Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 53. Global Sales Market Share of Acute Migraine Medications by Type (2020-2031)
 Figure 54. Global Revenue Market Share of Acute Migraine Medications by Type (2020-2031)
 Figure 55. Global Acute Migraine Medications Price (US$/Unit) by Type (2020-2031)
 Figure 56. Global Sales Market Share of Acute Migraine Medications by Application (2020-2031)
 Figure 57. Global Revenue Market Share of Acute Migraine Medications by Application (2020-2031)
 Figure 58. Global Acute Migraine Medications Price (US$/Unit) by Application (2020-2031)
 Figure 59. Acute Migraine Medications Value Chain
 Figure 60. Channels of Distribution (Direct Vs Distribution)
 Figure 61. Bottom-up and Top-down Approaches for This Report
 Figure 62. Data Triangulation
 Figure 63. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Samsung SD

SIMILAR REPORTS

Global Acute Migraine Treatments Market Research Report 2024
Migraine Treatment Medication Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Migraine Headache Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Chronic Migraine Treatment Market Research Report 2024
Prescription Migraine Medicine Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Prescription Migraine Medication Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Prescription Headache Medicine Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Migraine Therapeutics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Migraine Medication Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Digital Migraine Treatment Device Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
OTC Migraine Medication Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
OTC Migraine Medicine Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Epilepsy Devices Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Epilepsy Therapeutics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Triptans for Migraine Headaches Market Research Report 2025
Headache Medicine Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Migraine Drugs Market Research Report 2025
OTC Headache Medicine Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Preventive Treatment of Migraines Market Research Report 2024
Global Migraine Wearables Market Research Report 2024
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions